-+ 0.00%
-+ 0.00%
-+ 0.00%

Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot

Benzinga·11/19/2026 13:10:41
Listen to the news

On Wednesday, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Livsayis (cemdisiran) for generalized myasthenia gravis (gMG) in adults who test positive for anti-acetylcholine receptor (AChR) antibodies, the predominant form of the disease.

Livsayis stands as the first and only approved small interfering RNA (siRNA) therapy for gMG. It also represents the only FDA-approved gMG treatment that patients receive subcutaneously four times a year.

This novel therapeutic targets complement component factor 5 (C5) to reduce circulating C5 protein levels, limiting terminal complement activation, a key driver of the disease.

Livsayis Delivers Rapid Symptom Relief In Phase 3 Trial

The FDA based its approval on findings from the Phase 3 NIMBLE trial. At 24 weeks, Livsayis produced a 4.5-point least-squares mean improvement from baseline on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score, versus 2.2 points for placebo, reflecting a 2.3-point placebo-adjusted gain.

Clinicians use the MG-ADL scale to evaluate patient-reported daily functions, including talking, chewing, swallowing, breathing, vision, and mobility.

In the trial, 76.6% of Livsayis patients achieved at least a 3-point MG-ADL improvement at week 24, outpacing the 44.1% placebo responder rate.

Patients also recorded strong gains on the Quantitative Myasthenia Gravis (QMG) muscle function scale, which assesses vision, speaking, swallowing, breathing, and limb mobility.

Livsayis generated a 4.2-point QMG improvement at 24 weeks versus 1.5 points for placebo, delivering a 2.8-point placebo-adjusted benefit. Additionally, 48.4% of Livsayis patients achieved at least a 5-point QMG improvement at week 24, versus 19.0% on placebo.

Livsayis delivered rapid relief, sparking a clinically meaningful 2.5-point MG-ADL improvement within two weeks that deepened over time.

Patients sustained this symptom relief and disease control through 24 weeks without signs of waning efficacy.

Global Regulatory Review And International Expansion

European Union regulators are reviewing a submission for Livsayis in gMG, and officials anticipate a decision in the second half of 2027.

Regeneron also plans regulatory submissions in additional markets, including Japan.

Livsayis was discovered by Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and advanced into Phase 2 development by Alnylam before becoming part of an RNAi collaboration with Regeneron.

In 2024, Regeneron assumed sole responsibility for development, manufacturing, and commercialization of the molecule.

Per the agreement with Regeneron, Alnylam will receive a $25 million payment for the approval and is eligible to receive tiered, double-digit royalties of up to 15% on global net sales.

REGN Price Action: Regeneron Pharmaceuticals shares were up 0.26% at $948.00 during premarket trading on Thursday, according to Benzinga Pro data.

Photo via Shutterstock